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Abstract
Introduction: Pulmonary rehabilitation (PR) is an effective approach for patients with chronic pulmonary disease, and it is also 
recommended for patients with bronchiectasis. The aims of the current study were to evaluate the efficacy of a multidisciplinary 
PR program and identify factors associated with improvement in patients with bronchiectasis.
Material and ethods: We obtained data from patients with bronchiectasis who completed our PR program which consisted of 
education and training regarding bronchial hygiene. Pulmonary function test results, body composition, exercise capacity, quality 
of life, and psychological status were assessed before and after the PR program.
Results: We enrolled 130 patients in this retrospective study. Most patients had a history of pneumonia. The Medical Research 
Council (MRC) dyspnea scale, incremental shuttle walking test (ISWT), endurance shuttle walking test (ESWT), St. George’s 
Respiratory Questionnaire (SGRQ), Chronic Respiratory Questionnaire (CRQ), and Hospital Anxiety and Depression (HAD) scores 
statistically improved after the PR program (all p < 0.001). Improvements were similar regardless of sex, etiology, smoking sta-
tus, or number of hospitalizations. Age was negatively correlated with ΔSGRQ (p = 0.024, r = -0.203). Baseline forced expiratory 
volume in 1s (FEV1) was positively correlated with ΔCRQ (p = 0.015, r = 0.213) and negatively correlated with Δanxiety (p = 
0.014, r = -0.215). Baseline MRC was negatively correlated with ΔMRC (p < 0.001, r = -0.563) and ΔSGRQ (p < 0.001, r = 
-0.308). Baseline ISWT was negatively correlated with ΔISWT (p = 0.043, r = -0.176) and Δanxiety (p = 0.007, r = -0.237). 
Baseline SGRQ was negatively correlated with ΔMRC (p = 0.003, r = -0.267) and ΔSGRQ (p < 0.001, r = -0.648).
Conclusions: Our PR program is efficacious for patients with bronchiectasis regardless of sex, etiologic cause of bronchiectasis, 
concomitant chronic obstructive pulmonary disease, smoking status, and/or number of hospitalizations. Improvement varied 
among patients which highlights the need for more studies to determine which patients will benefit most from the program.
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Introduction
Bronchiectasis is a chronic disease charac-
terized by permanently dilated airways. Possible 
underlying mechanisms include inflammation, 
structural airway damage, impaired mucociliary 
clearance, and infection [1]. 
The main signs of bronchiectasis are dys-
pnea, cough, and exercise intolerance [2]. Re-
current infection, chronic respiratory symptoms, 
and limited exercise capacity result in a poorer 
quality of life [3]. Treatment requires reduction of 
clinical symptoms such as dyspnea and exercise 
intolerance in order to improve quality of life and 
reduce the number of recurrent infections.
Pulmonary rehabilitation (PR) is a compre-
hensive multidisciplinary approach for patients 
with chronic lung disease, functional limitation, 
and dyspnea. PR includes exercise training, edu-
cation, behavioral modification, and components 
of nutritional and psychosocial support [4, 5]. 
Guidelines for the management of bronchiectasis 
highlight the importance of PR [6–9] regardless 
of disease severity, pulmonary function, or the 
findings of high-resolution computed tomog-
raphy (HRCT). Although PR is an efficacious 
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intervention, the factors that modulate its effects 
have not been determined. The aims of the cur-
rent study were to evaluate the efficacy of our 
multidisciplinary PR program and the factors 




This was a retrospective observational cohort 
study. We obtained data from patients included 
in the database of our PR center, which is a refer-
ral center in a tertiary chest disease hospital in 
the capital city of our country. We evaluated the 
data of patients who completed our PR program 
between March 2013 and March 2019. Informed 
consent was obtained from all patients and in-
formation about the PR program was provided 
before it began. The consent form stated that data 
regarding the parameters of interest and patient 
information would be recorded. Approval for 
this study was obtained from our hospital review 
board.
Patient characteristics
All diagnoses were confirmed by our chest 
physician who reviewed each patient’s medical 
history, health records, physical examination re-
sults, chest radiographs, thorax HRCT scans, and 
pulmonary function tests. We also reviewed the 
genetic test results of patients with genetic disor-
ders or immune deficiencies. Chronic obstructive 
pulmonary disease (COPD) was diagnosed ac-
cording to the criteria of the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) [10].
We included patients who completed the PR 
program and had no missing data, had COPD, 
varicose and/or cystic bronchiectasis, emphysema 
on HRCT, and no acute infection (as confirmed by 
review of the medical history, serum C-reactive 
protein level, and chest radiography and HRCT 
findings). We excluded patients who had an 
exacerbation of disease during the PR program. 
PR program
The PR program was a comprehensive, mul-
tidisciplinary, hospital-based, and supervised 
outpatient program. PR was performed twice per 
week, and the patient also completed one unsu-
pervised home exercise session per week. The 
program consisted of exercise training, psycholog-
ical support, nutritional support, and educational 
courses (on disease pathology, disease exacerba-
tion control, medications, nutrition, bronchial 
hygiene, breath control techniques, energy con-
servation, and relaxation). The educational cours-
es were provided by a pulmonologist, three phys-
iotherapists, a dietician, a respiratory nurse, and 
a psychologist. The PR program was tailored to 
suit the needs of each individual patient. 
Bronchial hygiene involved a series of exer-
cises performed in a sitting position and designed 
to promote breathing control, thorax expansion 
after holding an inspired breath, and forceful 
expiration of the breath [11, 12]. Each patient 
performed these exercises before every training 
session for 15–20 min. Patients and caregivers 
were also educated about postural drainage, man-
ually assisted thoracic-abdominal compression, 
and controlled coughing [11, 12]. A physiother-
apist applied the techniques before a session if 
necessary.
The training sessions included cycle ergome-
try and treadmill training (15 min each), strength 
training of both the upper and lower extremities 
(5–10 min), and breathing and relaxation thera-
pies (15–20 min each). Patients performed these 
exercises for a total of 70–90 min/day. Workloads 
during cycling and walking were calculated based 
on the results of the incremental shuttle walk-
ing test (ISWT). Patients were trained at 50% of 
their peak workload on the cycle ergometer, and 
60–85% of peak oxygen consumption (VO2) on 
the treadmill. Exercise intensity was increased 
according to the progress of the individual pa-
tient. Strength training of the upper and lower 
extremities was performed according to each 
patient’s one-repetition maximum (1RM). Each 
patient performed two sets at 45–50% of the 1RM, 
and then performed 10 repetitions per set for the 
first 3–5 sessions. For the following sessions, the 
weight was increased to 70% of the 1RM. Phys-
iotherapists closely supervised the patients, and 
heart rate, blood pressure, and oxygen saturation 
(SpO2) were monitored during the training ses-
sions. Supplemental oxygen was administered 
to maintain oxygen saturation above 90% [13].
Outcome measures
Exercise capacity, quality of life, sensation of 
dyspnea, pulmonary function, body composition, 
and psychological status were recorded at base-
line and immediately after the PR program. We 
also recorded smoking status and the number of 
hospitalizations in the previous year.
Exercise capacity was evaluated with the 
ISWT and endurance shuttle walking test (ESWT) 
[14]. The tests were performed according to guide-
lines for field walking tests [15]. The minimal 
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clinically important difference (MCID) of ISWT 
is 47.5 m [16].
Health-related quality of life was assessed 
with the St. George’s Respiratory Questionnaire 
(SGRQ) and the Chronic Respiratory Question-
naire (CRQ). A 4-point change in the SGRQ total 
score corresponds to the MCID (17), while the 
MCID of the CRQ is 0.5 points [18]. Dyspnea 
was assessed with the Medical Research Council 
(MRC) dyspnea scale.
We used a spirometer (AS-507; Minato Med-
ical Science, Tokyo, Japan) to determine forced 
vital capacity (FVC), forced expiratory volume in 
1s (FEV1), and the FEV1/FVC ratio. Spirometry was 
performed in accordance with the guidelines of 
the American Thoracic Society/European Respi-
ratory Society [19]. We used a TANITA analyzer 
(TBF-300A Total Body Composition Analyzer; 
TANITA, Tokyo, Japan) to measure bioelectrical 
impedance and body composition. Body mass 
index (BMI) and the fat-free mass index (FFMI) 
were calculated as weight in kilograms divided 
by the square of height in meters (body mass was 
used to calculate BMI; fat-free mass was used to 
calculate FFMI). Hospital Anxiety and Depression 
(HAD) scores were used to assess psychological 
status [20].
Statistical analysis
We used SPSS for Windows software (version 
18.0; SPSS, Inc., Chicago, IL, USA) to perform 
the statistical analysis. Assuming a two-sided 
alpha level of 0.05, we performed Cohen’s d 
analysis [21] with G*Power 3.1.9.2 software 
(Heinrich-Heine-Universität, Düsseldorf, Ger-
many) to determine that the beta level was 
0.20 and the effect size was medium. We used 
the Shapiro-Wilk test to evaluate the distribu-
tions of the variables. Descriptive statistics are 
expressed as mean ± standard deviation or me-
dian (range). Categorical variables are expressed 
as number and percentage (%). Improvements in 
parameters were calculated by subtracting the 
absolute pre-PR value from the post-PR value, 
denoted by ‘Δ’.
 We compared continuous variables among 
groups with one-way analysis of variance or the 
Kruskal-Wallis test. Spearman correlation anal-
ysis was also performed. Pre-post values were 
analyzed with the Wilcoxon signed-rank test 
(for non-normally distributed data) or the paired 
T-test (for normally distributed data). Binary 
logistic regression was used to assess the asso-
ciation between sex and score improvement. All 
other associations were analyzed by regression 
analysis. Baseline ISWT and FEV1 were adjusted 
for age, sex, and BMI. P < 0.05 indicates statistical 
significance.
Results 
We enrolled 130 patients who completed the 
PR program. Sixty-eight (52%) patients were men. 
The mean age was 47 ± 15 years. Five (4%) pa-
tients were current smokers, forty-one (31%) were 
former smokers, and eighty-four (65%) had never 
smoked. In total, 78 (60%) patients had a history 
of pneumonia, 33 (24%) had concomitant COPD, 
8 (6%) had a history of tuberculosis, 2 (2%) had 
immune deficiency, 3 (2%) had Kartagener syn-
drome, 4 (3%) had primary ciliary dyskinesia, and 
2 (2%) had cystic fibrosis. Seventy-eight (58%) 
patients had an obstruction according to the 
pulmonary functional test. The mean FEV1 was 
42% ± 19% and the mean FVC was 53% ± 21% 
of the predicted value.
MRC, ISWT, ESWT, SGRQ, CRQ, and HAD 
scores were significantly higher after the PR pro-
gram (p < 0.001). The improvements exceeded 
the MCID values.
We also investigated the relationships of 
the improvements in MRC, ISWT, ESWT, SGRQ, 
CRQ, and HAD scores with age, sex, presence 
of concomitant or underlying disease, number 
of hospitalizations, and baseline FEV1, MRC, 
ISWT, and SGRQ scores/values (Figures 1–3). The 
improvements were not associated with sex, un-
derlying disease, smoking status, or the number 
of hospitalizations in the previous year. Age was 
negatively correlated with ΔSGRQ (p = 0.024, r = 
−0.203). Baseline FEV1 was positively correlated 
with ΔCRQ (p = 0.015, r = 0.213) but negatively 
correlated with Δanxiety (p = 0.014, r = -0.215). 
Baseline MRC was negatively correlated with 
ΔMRC (p < 0.001, r = -0.563) and ΔSGRQ (p < 
0.001, r = -0.308). Baseline ISWT was negatively 
correlated with ΔISWT (p = 0.043, r = -0.176) and 
Δanxiety (p = 0.007, r = -0.237). Baseline SGRQ 
was negatively correlated with ΔMRC (p = 0.003, 
r = -0.267) and ΔSGRQ (p < 0.001, r = -0.648).
Discussion
Multidisciplinary PR proved to be an effi-
cacious approach for improving dyspnea, exer-
cise capacity, quality of life, and psychological 
status in patients with bronchiectasis regardless 
of sex, etiology of bronchiectasis, presence of 
concomitant COPD, smoking status, and/or the 
number of hospitalizations in the previous year 
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Figure 1. The relation between baseline St. George’s Respiratory Questionnaire (SGRQ) and ΔSGRQ
Figure 2. The relation between baseline St. George’s Respiratory Questionnaire (SGRQ) and Δ Medical Research Council (MRC)
(Tables 1, 2). Improvements in quality of life 
were greater among patients who were younger 
and had less severe dyspnea, better quality of 
life, and better FEV1 at baseline. Improvements 
in dyspnea were greater among patients who 
had less severe dyspnea and a better quality of 
life at baseline. Patients who had lower exercise 
capacity or FEV1 showed greater improvements 
in anxiety scores, and patients who had poorer 
exercise capacity showed greater improvements 
in exercise capacity. 
Bronchiectasis is associated with a variety of 
common and rare diseases, some of which impact 
mucociliary clearance and immunity. Immune 
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Figure 3. The relation between baseline incremental shuttle walking test (ISTW) and ΔISWT







Current/former/never smoker 5 (4%) / 41 (31%) / 84 (65%)
Cigaratte 10 ± 20 (0:90)
FEV1% predicted 42 ± 19 43 ± 19 0.475
FVC% predicted 53 ± 21 53 ± 20 0.723
FEV1/FVC 66 ± 13 65 ± 14 0.213
BMI [kg/m2] 25 ± 7 25 ± 6 0.207
FFMI [kg/m2] 18 ± 3 18 ± 3 0.313
MRC scale 3 ± 1 2 ± 1 < 0.001
ISWT [m] 250 ± 137 310 ± 144 < 0.001
ESWT [min] 8 ± 7 13 ± 8 < 0.001
CRQ total score 67 ± 16 91 ± 20 < 0.001
SGRQ-total score 64 ± 17 37 ± 14 < 0.001





PR — pulmonary rehabilitation; FEV1 — forced expiratory volume in 1 sec; FVC — forced vital capacity; BMI — body mass Index; FFMI — fat-free mass index; 
MRC — Medical Research Council; ISWT — incremental shuttle walking test; ESWT — endurance shuttle walking test; CRQ — chronic respiratory questionnaire; 
SGRQ — St. George’s Respiratory Questionnaire; HAD — hospital axiety and depression
deficiency syndromes and metabolic pathologic 
conditions are the most common etiologies of 
bronchiectasis in developed countries, while 
bacterial and viral infections are major causes 
of bronchiectasis in developing countries [22]. 
In our study, the most common etiology was 
a history of pneumonia. As expected, genetic and 
immunologic disorders were uncommon because 
we only included adult patients (mean age of 
47 ± 15 years).
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Bronchiectasis can coexist with other lung 
diseases such as COPD. In our study, 33 (24%) 
patients had COPD. In another study from our 
country, the mean age of 304 patients with bron-
chiectasis was 56 ± 25 years; 65.8% of patients 
were non-smokers and 47.4% showed obstruction 
on pulmonary function tests [23]. In our study, 
65% of the patients had never smoked and 58% 
had an obstruction. Obstruction may be associ-
ated with concomitant COPD, and bronchiectasis 
itself may also cause obstruction.
The main clinical manifestations of bronchi-
ectasis are chronic cough, sputum production, dys-
pnea, fatigue, anxiety, depression, and functional 
limitations that negatively impact quality of life 
[1]. In our study, patients had dyspnea, limited 
exercise capacity, poor quality of life, borderline 
anxiety, and depression. Several studies have 
shown the positive impacts of PR, especially on 
exercise capacity and quality of life [24–28]. Recent 
guidelines also emphasize PR in the management 
of bronchiectasis [6–8]. In our study, after comple-
tion of the multidisciplinary PR program, patients 
showed significant improvements in dyspnea, 
exercise capacity, quality of life, and psychological 
status. It is important to note that these improve-
ments exceeded the MCID values. In a recent re-
view, ISWT increased from 52 to 82 m in patients 
with bronchiectasis after PR [25]. In our study, 
ISWT increased by 60m. In another study, the total 
CRQ score increased by 12.8 after completion of 
a multidisciplinary PR program [29]. In our study, 
the total CRQ score increased by 24 points. Other 
studies may have enrolled patients with signifi-
cantly different baseline CRQ scores and exercise 
capacities although, similar to our study, another 
recent study reported that HAD scores changed 
in response to PR in patients with bronchiectasis 
with an estimated MCID of -2 points [30].
The short and long-term outcomes of PR for 
patients with bronchiectasis have been evaluated 
in several studies of various PR programs and these 
studies concluded that the degree of improvement 
in exercise capacity was not affected by program 
intensity or duration [1]. Our program, which was 
conducted in accordance with recent guidelines, 
was a comprehensive, multidisciplinary, hospi-
tal-based, and supervised outpatient program where 
all the components were tailored to the needs of 
the individual patient. Education, an important 
component of PR programs, is an issue in patients 
with bronchiectasis. In a previous study, quality of 
life improved in patients with bronchiectasis even 
after they received only education [31]. A recent 
review asserted that education should include 
bronchial hygiene and breath control techniques 
which improve sputum expectoration, certain 
measures of lung function, symptoms, and quality 
of life [32, 33]. All airway clearance techniques 
showed similar clinical outcomes [31]. We believe 
that education about airway clearance techniques 
may have improved the outcomes of our patients. 
Table 2. Relation between some baseline values and improvements
p/r*
Baseline values ΔMRC ΔISWT ΔESWT ΔSGRQ ΔCRQ ΔAnxiety ΔDepression
Age [years]** 0.077 0.521 0.085 0.024
-0.203
0.875 0.221 0.093
Sex# 0.689 0.882 0.957 0.585 0.648 0.079 0.192
Hospitalization£ 0.095 0.486 0.756 0.518 0.555 0.332 0.110
Disease$ 0.220 0.890 0.651 0.335 0.135 0.438 0.997
Smoking status$ 0.110 0.491 0.188 0.312 0.325 0.250 0.174





Baseline MRC** < 0.001 
-0.563
0.822 0.488 < 0.001
-0.308
0.106 0.289 0.358
Baseline ISWT+ 0.129 0.043
-0.176





0.958 0.207 < 0.001
-0.648
0.478 0.349 0.158
*Correlation coefficients were given when p values were statistically significant; **spearmans’ correlation; #Binary logistic regression; £Linear regression; $Kruskal-Wal-
lis test; +Adjusted for age, sex, and BMI using linear regression analysis
FEV1 — forced expiratory volume in 1 sec; MRC — Medical Research Council; ISWT — incremental shuttle walking test; SGRQ — St. George’s Respiratory Ques-
tionnaire
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Few studies have investigated the factors 
predicting the efficacy of PR in patients with 
bronchiectasis [24, 26]. In a recent review, most 
studies of patients with COPD indicated that PR 
can be effective for patients of any age in terms 
of improving exercise capacity, health status, and 
anxiety and depression [34, 35]. Similarly, in our 
study, age was not associated with improvements 
in exercise capacity or anxiety and depression, 
but it was associated with an improved quality of 
life. In a propensity-matched control study that 
compared patients with bronchiectasis to those 
with COPD, similar improvements in exercise, 
quality of life, and CRQ scores were seen [29]. 
In our study, dyspnea, exercise capacity, quality 
of life, and psychological status improved re-
gardless of concomitant COPD. In another study, 
108 patients with bronchiectasis who completed 
a 3-week PR program showed improvements in 
exercise capacity and quality of life. In this same 
study, male sex, baseline FEV1, vital capacity 
less than 70%, and more than two disease exac-
erbations in the previous year were independent 
predictors of PR efficacy [27]. In another study, 
41 patients with bronchiectasis underwent PR. 
After PR, pulmonary function, arterial blood gas 
levels, and 6-minute walking distance (6MWD) 
improved. However, they did not improve sig-
nificantly, and PR outcomes were not associated 
with sex, bacterial colonization, or disease exac-
erbation [24]. In our study, sex and the number 
of hospitalizations were not associated with im-
proved outcomes, and only low exercise capacity 
at baseline was associated with an improvement 
in exercise capacity. This may have been due to 
the enrollment of a heterogeneous group of young-
er patients with lower baseline exercise capacity 
compared to the patients enrolled in the other 
two studies. Similar to our findings, patients with 
COPD and limited exercise capacity had higher 
exercise capacity after PR [36, 37].
The efficacy of PR has been proven but the 
factors associated with beneficial outcomes and 
the patients that respond best have not been de-
termined. In another study, patients with COPD 
and MRC grade 5 dyspnea showed smaller im-
provements in exercise capacity and quality of 
life after PR in comparison with patients with less 
severe dyspnea [38]. Similar to the patients in our 
study, patients with less severe dyspnea showed 
greater improvements in quality of life. In a mul-
ticenter study of patients after completion of a PR 
program, 2,068 patients with COPD and 49% of 
predicted FEV1 were grouped according to MRC, 
6MWD, endurance time, scores on measures of 
performance and satisfaction, and HAD and total 
SGRQ scores. Patients in the “very good respond-
er” group had more severe signs of dyspnea, more 
hospitalizations, and worse exercise performance, 
satisfaction scores, anxiety, depression, and health 
status [39]. In our study, improvements in qual-
ity of life were greater among patients who were 
younger, had less severe dyspnea, and had a better 
quality of life and FEV1 at baseline. Patients who 
had lower exercise capacity or FEV1 showed greater 
improvements in anxiety scores. These findings 
may have been due to the study design, number 
of patients enrolled, and exercise capacity and 
diagnoses thereof. Although the mechanisms un-
derlying dyspnea and quality of life may be similar 
between patients with COPD and those with bron-
chiectasis, these mechanisms are multifactorial 
and other as-yet unidentified factors may exist.
A major limitation of this study was its sin-
gle-center design which limits the generalizability 
of the results. 
Conclusion 
Multidisciplinary PR is an efficacious ap-
proach to improve dyspnea, exercise capacity, 
quality of life, and psychological status in patients 
with bronchiectasis regardless of sex, etiology of 
bronchiectasis, presence of concomitant COPD, 
smoking status, and the number of hospitaliza-
tions in the previous year. Improvements in qual-
ity of life and dyspnea were greater for patients 
who were younger, had less severe dyspnea, and 
had better FEV1. Improvements in quality of life, 
exercise capacity, and anxiety were greater for 
patients who had poorer exercise capacity and 
FEV1 at baseline. All patients with bronchiectasis 
should be referred for PR regardless of age, pul-
monary function, exercise capacity, and quality 
of life because their outcomes may be improved. 
More studies are needed to determine which pa-
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